Shared Pathways Link Autism and Alzheimer’s, but Causality Remains Unproven

A 2026 review argues that autism spectrum disorder and Alzheimer’s disease are not governed by entirely separate biological systems, despite their contrasting clinical courses. Autism typically emerges during early brain development, whereas Alzheimer’s disease develops later through progressive neuronal loss, protein aggregation and cognitive decline. By comparing genetic, cellular, epidemiological and imaging evidence, the authors identify overlapping pathways involving mTOR signaling, autophagy, synaptic architecture, epigenetic regulation, complement-mediated pruning, mitochondrial function, neuroinflammation and glymphatic clearance. Their central proposal is a shared-vulnerability framework, but the review stresses that molecular convergence does not show that autism causes Alzheimer’s disease or that most autistic adults will develop it.

Large-scale gene comparisons have identified at least 148 genes associated with both conditions, with 75, or 50.7%, connected to mechanistic target of rapamycin, or mTOR, signaling. This intersection includes genes such as CTNNB1, CREBBP, TRAF2, HDAC1 and HDAC2, which participate in protein synthesis, chromatin remodeling, synaptic plasticity and inflammatory signaling. The overlap is best interpreted as a shared regulatory architecture: many genetic influences appear to converge on a limited number of downstream biological processes. It does not establish a single pathway that produces both disorders. Indeed, a Mendelian randomization analysis cited in the review found that genetic liability to Alzheimer’s disease did not significantly increase the risk of autism spectrum disorder or attention-deficit/hyperactivity disorder.

Human evidence comes from studies of autistic adults and people with rare genetic neurodevelopmental conditions. A systematic review of 14 rare genetic neurodevelopmental disorders identified 49 clinically confirmed dementia cases with an average onset age of 44.4 years, substantially earlier than the typical onset of sporadic Alzheimer’s disease at 65 to 70 years. Epilepsy, psychotic disorders and movement disorders frequently contributed to cognitive decline, while biomarker evaluation was absent in 51% of cases. Population studies also suggest an increased burden of early-onset dementia among autistic adults younger than 65, but they did not distinguish Alzheimer’s disease from other dementias or consistently separate idiopathic from syndromic autism. These findings demonstrate an association, not a diagnosis-specific or causal relationship.

Fragile X-associated tremor/ataxia syndrome provides one of the clearest bridges between developmental and neurodegenerative biology. Full CGG-repeat expansions in FMR1 cause fragile X syndrome through transcriptional silencing and loss of FMRP, whereas premutation carriers produce excess FMR1 RNA, form intranuclear inclusions and may develop progressive tremor, ataxia, cognitive decline and neuropathy after age 50. Approximately 40% of male and 16% of female premutation carriers are reported to develop the syndrome. Phelan–McDermid syndrome offers another example: an estimated 30% to 50% of affected individuals experience neurological regression during adolescence or early adulthood. A multimodal study found elevated cerebrospinal-fluid neurofilament light chain and tau in a subset of adults with regression, alongside progressive cortical and subcortical volume loss, consistent with active neuronal injury but not proof of Alzheimer’s pathology.

Several cellular systems could explain why developmental abnormalities and later degeneration may intersect. SHANK3 organizes the postsynaptic density, and its loss in Phelan–McDermid syndrome alters the material properties of synaptic condensates; SHANK3 expression also decreases as Alzheimer’s disease progresses. Complement proteins normally mark synapses for developmental removal, but inappropriate reactivation in Alzheimer’s disease can drive synapse loss, with C1q messenger RNA reported to rise by as much as 80-fold in vulnerable regions. Epigenetic control is similarly divergent in direction: reduced developmental methyltransferase activity is associated with epigenetic immaturity in autism, whereas increased G9a/EHMT2 activity and H3K9 methylation correlate with Alzheimer’s severity. The same network can produce different outcomes depending on timing, cell type and the biological function being stressed.

Metabolic and immune pathways add further overlap but also important uncertainty. Mitochondrial impairment, oxidative stress, altered tryptophan–kynurenine metabolism, sphingolipid dysregulation and purinergic signaling appear in both disorders. In a 2026 pooled CRISPR screen targeting 23 neurodevelopmental-disorder risk genes in human stem-cell-derived neural progenitor, glutamatergic and GABAergic neurons, convergence was strongest in mature glutamatergic neurons, particularly in synaptic, epigenetic and mitochondrial networks. Immune findings include chronic microglial activation in autism and disease-associated microglia around amyloid plaques in Alzheimer’s disease. T-cell abnormalities and overlapping cytokine signals have been reported in both conditions, but the causal roles differ: inflammatory changes may be primary, secondary or subgroup-specific in autism, while their contribution to Alzheimer’s progression is stronger and more clearly stage-dependent.

One especially informative bridge is the APP–FMRP–mGluR5 axis. FMRP normally represses translation of amyloid precursor protein messenger RNA; loss of FMRP in fragile X models elevates soluble amyloid-beta species, and mGluR5 activation can lift this repression. Separately, an mGluR5 modulator prevented C1q localization at synapses and restored synapse density in aged Alzheimer’s disease mice. Reduced mGluR5 availability has also been observed by positron-emission tomography in adults with autism. These findings make mGluR5 a candidate cross-condition research target, but they do not demonstrate that a drug benefiting one population will treat the other. Similarly, mTOR inhibition can reduce pathological protein accumulation in neuronal models while suppressing TREM2-dependent amyloid clearance by microglia, illustrating why cell-specific effects are critical.

Biomarker development may reveal whether these overlaps matter over time. Alzheimer’s disease already has validated amyloid, tau and neurodegeneration frameworks, including plasma phosphorylated-tau 217, neurofilament light chain and GFAP measures, while autism lacks a comparably validated biomarker panel. Reduced diffusion tensor imaging along the perivascular space, an indirect marker associated with glymphatic fluid movement, has been reported independently in children with autism and people with Alzheimer’s dementia. A 39-person randomized crossover trial also found that normal sleep increased morning plasma concentrations of Alzheimer’s biomarkers compared with sleep deprivation, consistent with sleep-dependent clearance. Prospective studies are now needed to determine whether early developmental differences in clearance, synaptic pruning or epigenetic timing predict later changes in amyloid, tau or neurodegeneration markers.

The review’s most provocative proposal is that autism may involve domain-specific heterochrony, or altered timing of developmental processes, rather than a uniform delay. Persistent early sensory and local-processing patterns, atypical connectivity maturation and excessive retention of immature synapses could leave certain systems biologically “off schedule.” The authors hypothesize that the same mTOR–autophagy, complement, epigenetic and waste-clearance mechanisms that disrupt early circuit refinement might also be less resilient to the proteostatic and metabolic demands of aging. They frame this as an evolutionary trade-off between developmental connectivity, metabolic cost and long-term resilience, rather than as an established progression from autism to Alzheimer’s disease. The decisive test will be longitudinal, biologically phenotyped cohorts that follow autistic and other neurodevelopmental groups as they age, distinguish specific dementias, measure baseline developmental differences and repeatedly track validated neurodegeneration biomarkers.

Subject of Research: Review of shared molecular mechanisms and possible developmental vulnerabilities linking autism spectrum disorder and Alzheimer’s disease

Article Title: From developmental divergence to degenerative vulnerability: convergent molecular mechanisms linking autism spectrum disorder and Alzheimer’s disease

Article References: Griñán-Ferré, C., Hussain, F., Bellver-Sanchis, A., Pérez-Salvador, N., Valle, Y., Ortuño-Sahagún, D., & Arias-Carrión, O. (2026). From developmental divergence to degenerative vulnerability: convergent molecular mechanisms linking autism spectrum disorder and Alzheimer’s disease. Frontiers in Molecular Neuroscience, 19, Article 1963972. https://doi.org/10.3389/fnmol.2026.1963972

Image Credits: AI Generated

DOI: 10.3389/fnmol.2026.1963972

Keywords: autism spectrum disorder, Alzheimer’s disease, mTOR signaling, autophagy, synaptic pruning, epigenetic regulation, neuroinflammation, glymphatic clearance, heterochrony, neurodegeneration, developmental, divergence